Statin Intake and All-Cause Mortality among Older Nursing Home Residents

Gerontology. 2022;68(4):407-411. doi: 10.1159/000516862. Epub 2021 Jun 16.

Abstract

Background: Statins are progressively accepted as being associated with reduced mortality. However, few real-world statin studies have been conducted on statin use in older people and especially the most frail, that is, the nursing home residents.

Objective: The aim of this study was to evaluate the impact of statin intake in nursing home residents on all-cause mortality.

Method: This is a cross-sectional study of 1,094 older people residing in 6 nursing homes in Flanders (Belgium) between March 1, 2020 and May 30, 2020. We considered all residents who were taking statins for at least 5 days as statin users. All-cause mortality during the 3 months of data collection was the primary outcome. Propensity score overlap-weighted logistic regression models were applied with age, sex, functional status, diabetes, and cardiac failure/ischemia as potential confounders.

Results: 185 out of 1,094 residents were on statin therapy (17%). The statin intake was associated with decreased all-cause mortality: 4% absolute risk reduction; adjusted odds ratio 0.50; CI 0.31-0.81, p = 0.005.

Conclusions: The statin intake was associated with decreased all-cause mortality in older people residing in nursing homes. More in-depth studies investigating the potential geroprotector effect of statins in this population are needed.

Keywords: Aging; Geroprotector; Life span; Nursing homes; Statins.

Publication types

  • News
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Coronary Artery Disease*
  • Cross-Sectional Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Nursing Homes
  • Odds Ratio

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors